FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Levy Richard S</u>					2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]					(Che	elationship of the control of the co	cable)	Reporting Person(s) to Issuer ble) 10% Owner			
	IKSA PHA	RMACEUTICA	1		3. Date of Earliest Transaction (Month/Da 06/29/2022							Officer below)	(give title	Other (s below)	pecify	
CLARENDON HOUSE 2 CHURCH STREET  (Street)  HAMILTON D0 HM 11				4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)	) Dominios ti	60	ouvitio.		auirad Di	on a sad a	of or Do	a oficial!	. Owned				
				Transacti ate Ionth/Day	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transactic Code (Inst	4. Securi Disposed 5)  Amount	ties Acquired Of (D) (Ins	Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form	: Direct   C Indirect   I str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)	
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year)		e, 4. Tran	5. Number of Derivative		Expiration Date of Sec (Month/Day/Year) Under Deriva		7. Title and of Securiti Underlying Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Blly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Share Option	\$9.88	06/29/2022		A		30,000		(1)	06/28/2032	Class A Common Shares	30,000	\$0	30,000	0	D	
Restricted Share Units	(2)	06/29/2022		A		5,000		(3)	(3)	Class A Common Shares	5,000	\$0	5,000		D	

## **Explanation of Responses:**

- 1. The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022.
- 2. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
- 3. The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022.

/s/ Madelyn Zeylikman, Attorney-in-Fact

06/30/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.